Lubiprostone (Amitiza)

What is Lubiprostone?

Lubiprostone, marketed under the brand name Amitiza in some markets, is a bicyclic fatty acid derived from prostaglandin E1. It is classified as a selective chloride channel activator and has the following US indications, not established here as Spanish indications:

• Chronic Idiopathic Constipation (CIC): Constipation without a known underlying cause, occurring in both men and women
• Irritable Bowel Syndrome with Constipation (IBS-C): In women aged 18 years or older
• Opioid-Induced Constipation (OIC): Constipation as a side effect of opioid pain medicines in adults with chronic non-cancer pain

Lubiprostone is a targeted pharmacological approach to constipation, working at the cellular level in the intestinal lining rather than stimulating gut contractions or acting via an osmotic mechanism.

How does Lubiprostone work?

Lubiprostone selectively activates type-2 chloride channels (ClC-2 channels) located in the apical membrane of intestinal epithelial cells — the cells lining the inner surface of the intestine. When these channels are activated:

1. Chloride secretion: Chloride ions flow from the epithelial cells into the intestinal lumen (the interior space of the gut).
2. Fluid follows: Sodium ions and water follow the chloride gradient via paracellular pathways, increasing intestinal fluid secretion.
3. Stool softening: The increased luminal fluid softens stool consistency.
4. Peristalsis facilitated: Softer, more fluid stool moves more easily through the colon, facilitating natural bowel movements.

Because Lubiprostone acts specifically on ClC-2 channels rather than on prostaglandin receptors systemically, its effects are largely localised to the intestinal lining. Systemic exposure is low, but dyspnoea, hypotension and syncope can still occur.

The US label describes effects on intestinal fluid and barrier function; this does not establish an anti-inflammatory treatment indication.

Who is Lubiprostone for?

A doctor may assess adults who:

• Have chronic constipation that has not responded adequately to dietary fibre, hydration optimisation, and conventional over-the-counter laxatives
• Are women aged 18 years or older with IBS-C, within the US indication
• Are experiencing constipation as a side effect of prescribed opioid pain medicines

Lubiprostone is not suitable for:

• Patients with known or suspected mechanical gastrointestinal obstruction (e.g., from adhesions, tumour, or stricture)
• Patients with severe diarrhoea
• Pregnancy requires individual benefit–risk assessment because animal studies suggest fetal harm; the current US label does not use a Category C designation
• Patients with known hypersensitivity to Lubiprostone

Lubiprostone requires assessment by a qualified doctor before initiation, as symptoms of constipation and IBS-C can overlap with conditions requiring different management.

Dosage

These are US Amitiza adult doses, not a Spanish prescribing policy. mcg means micrograms:

Swallow capsules whole with food and water; do not break or chew them. Food may reduce nausea. An independent doctor will prescribe the appropriate dose for your specific diagnosis and circumstances.

Under the US label, hepatic adjustment depends on indication:

Any later increase requires clinician assessment and monitoring. Effectiveness for OIC with methadone has not been established. Reassess the need for ongoing treatment periodically.

Side effects

Frequently reported effects

• Nausea: The most frequently reported side effect, reported in 29% of the US CIC trial population, not a rate for every indication. Food may reduce nausea.
• Diarrhoea: May occur, particularly with the 24 mcg dose.
• Abdominal pain or discomfort
• Headache
• Abdominal distension (bloating)

Other reported effects

• Flatulence (gas)
• Vomiting
• Fatigue
• Dizziness
• Oedema (fluid retention)

Symptoms requiring action

• Dyspnoea (shortness of breath): Reported in about 3% of treated CIC trial participants; rates differ by indication. It may start within 1 hour and recur with later doses. Contact a clinician promptly; do not assume breathlessness will resolve without assessment.
• Severe diarrhoea: Stop Amitiza and contact the prescriber; do not merely reduce the dose yourself.
• Syncope or hypotension: Stop and contact the prescriber if fainting or symptomatic low blood pressure occurs. Some reported cases required hospital care.

Lubiprostone vs other constipation treatments

A clinician selects treatment based on the cause and prior response. This mechanism comparison is not a recommendation or a statement of equivalent indications across countries.

Online assessment for Lubiprostone (Amitiza)

Prescrivia is a technology intermediary connecting patients with independent doctors and licensed pharmacies. We do not provide medical services, prescribe, employ doctors, sell or dispense medicines.

1. Assessment: Provide your symptoms or travel plans, medical history and all current medicines.
2. Independent review: A doctor decides whether a prescription is clinically appropriate; Prescrivia does not guarantee a prescription.
3. Dispensing: Any lawful dispensing is the responsibility of a licensed pharmacy, subject to the applicable rules and product availability.

In Spain, distance selling of prescription medicines is prohibited. An online assessment or a product label does not establish that a medicine can legally be supplied or delivered through this platform. This information does not change eligibility or fulfilment rules.

Important safety information

Do not take lubiprostone with known or suspected mechanical bowel obstruction. Avoid use with severe diarrhoea or a known allergy. Other safety issues:

• Pregnancy or pregnancy planning requires prescriber review before use; potential fetal harm remains a warning, not a US-labelled absolute contraindication

Tell your doctor if you:

• Have liver disease (moderate CIC/OIC and severe impairment across indications need different dose adjustments, as above)
• Experience new shortness of breath within an hour of your first dose
• Have severe diarrhoea at any point during treatment (stop and contact your doctor)

Seek urgent medical advice if you develop:

• New, severe, or sudden abdominal pain
• Blood in stools or black/tarry stools
• Unexplained weight loss

These may indicate conditions requiring urgent evaluation beyond the scope of constipation management.

Sources

• DailyMed: Amitiza, US prescribing information
• BOE: Real Decreto Legislativo 1/2015, article 3.5

General information, not individual medical advice. This US source does not establish a Spanish authorisation, clinical pathway or supply route.